High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children’s Oncology Group (COG) Study (AALL03N1)
Ravi Bhatia(University of Alabama at Birmingham), Mary V. Relling(St. Jude Children's Research Hospital), Lindsey Hageman(Tianjin Chengjian University), F. Lennie Wong(Tianjin Chengjian University), Anne Angiolillo(Children's National), William E. Evans(St. Jude Children's Research Hospital), A. Kim Ritchey(Children's Hospital of Pittsburgh), Jacqueline Casillas(University of California, Los Angeles), Can‐Lan Sun(University of Minnesota), Wendy Landier(University of Alabama at Birmingham), Leo Mascarenhas(University of Southern California), Kelly W. Maloney(Children's Hospital Colorado), William L. Carroll(NYU Langone Health), Heeyoung Kim(City of Hope), Nancy Kornegay(Tianjin Chengjian University), Jane L. Meza(Children's Oncology Group), Bruce Bostrom(Minnesota West Community & Technical College), Glen Lew(Emory University), Amanda Termuhlen
Cited by 7
Related Papers
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
|Cancer Cell|2002|1.9k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k